CBD for Arthritis: Promising Pain Research, but Not Yet a Steroid-Sparing Treatment
People with arthritis often look beyond conventional pain medicines when symptoms persist or medication side effects become difficult to manage. Cannabidiol (CBD), a non-intoxicating compound found in cannabis, is one option attracting interest. But current evidence does not establish CBD as a replacement for corticosteroids or as a proven steroid-sparing treatment for arthritis.
That distinction matters. A steroid-sparing therapy is intended to reduce a patient’s reliance on corticosteroids while continuing to control the underlying disease. Evidence that CBD might ease pain or inflammation is not the same as evidence that it can safely replace prednisone or other disease-modifying treatment.
What the research shows
A 2023 scoping review in the Rambam Maimonides Medical Journal examined laboratory, animal, clinical and observational research on cannabis and rheumatoid arthritis. The review described anti-inflammatory and pain-relieving effects in preclinical studies, including effects on inflammatory signaling and immune-cell activity. However, it also concluded that clinical research in patients remains limited and mixed, with no established clinical recommendations for using cannabis to treat rheumatoid diseases.
Consider a 2019 BMJ Open study involving CBD and a possible add-on of tetrahydrocannabinol (THC) for chronic pain in people with rheumatoid arthritis or ankylosing spondylitis. That paper was a study protocol—not a report of completed results. It described a planned randomized, placebo-controlled trial of oral CBD followed by an observational period in which some participants could receive THC. It therefore cannot be used as evidence that CBD was effective or well tolerated in those patients.
There is also a separate line of research involving CBD as a possible steroid-sparing therapy for conditions such as graft-versus-host disease, Crohn’s disease and autoimmune hepatitis. Those investigations do not demonstrate that CBD can reduce steroid use in people with arthritis. Findings from laboratory models, early-phase research or other diseases should not be presented as proof of benefit for rheumatoid or osteoarthritis.
Possible benefits—and important limits
CBD may influence pain pathways and inflammatory signaling, which provides a biological rationale for further study. Some people with arthritis report improvements in pain, sleep or anxiety after using CBD, but anecdotal reports cannot establish how well it works, which formulations are effective or what dose is appropriate.
Evidence for cannabis-based products in chronic pain generally suggests, at most, modest short-term benefits, and much of the research has involved products containing THC, CBD and other cannabinoids rather than CBD alone. A National Center for Complementary and Integrative Health summary notes that research on cannabinoids for conditions beyond a small number of established medical uses remains at an early stage.
CBD also has risks. It can cause drowsiness, diarrhea, changes in alertness and other gastrointestinal symptoms. It may affect the liver and can interact with prescription and over-the-counter medicines. The U.S. Food and Drug Administration discusses these concerns in its consumer information on CBD safety.
Over-the-counter products add another layer of uncertainty. They may contain more or less CBD than their labels state, undeclared THC or contaminants such as pesticides, heavy metals or solvents. Third-party laboratory testing and a certificate of analysis can provide useful information, but testing does not turn an unapproved product into a proven arthritis treatment.
CBD should not replace arthritis treatment
For inflammatory arthritis, CBD is not a substitute for disease-modifying antirheumatic drugs or other treatments prescribed to prevent joint damage. Corticosteroids should not be reduced or stopped abruptly; any change must be planned with the clinician managing the condition.
The Arthritis Foundation’s guidance on CBD for arthritis pain similarly emphasizes that high-quality clinical studies are still lacking. Anyone considering CBD should discuss the product, dose, possible drug interactions and treatment goals with a healthcare professional—particularly if they take prednisone, anti-inflammatory medicines, anticoagulants, antidepressants or other medications.
CBD remains a subject worth studying, especially for pain and symptom management. But based on the available evidence, it is more accurate to describe it as an unproven, potentially useful adjunct for some people—not as an established steroid-sparing treatment for arthritis.
